CClinicalTrials.gg
RecruitingNCT05663281TitanUpdated Jul 3, 2024

Thrombus Imaging and Treatment Analytics in Neurology

An observational study in Thrombus, Brain and Thrombosis, sponsored by Chinese PLA General Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-03.

Sponsored by Chinese PLA General Hospital · Observational

From the registry’s dates

  • Started Dec 2022; still recruiting 3 years 9 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Study summary

In the present study, the investigators use high-resolution MR vessel wall imaging, and select patients with cerebral and cervical artery occlusion to investigate the relationship between the imaging appearance of thrombus and the various outcome of recanalization treatment.

Read the detailed description

Cerebral ischemic stroke resulting from thrombosis causes high disability and mortality. There are few biomarkers to evaluate arterial thrombophilia until now. Previous studies have demonstrated that atherosclerotic plaque rupture and erosion are major etiologies initiating thrombosis. Based on previous works targeting the role of plaque and blood flow in cerebrovascular disease, in the present study, the investigators use high-resolution MR vessel wall imaging, and select patients with cerebral and cervical artery occlusion to explore the relationship between the imaging appearance of thrombus and the various outcome of recanalization treatment. The study's objective was to solve the challenges in the mechanism of thrombus features and the outcome of recanalization therapy, thus helping improve the primary and secondary prevention of cerebrovascular disease.

02

Conditions studied

  • Thrombus, Brain
  • Thrombosis

Keywords

  • Thrombus
  • Neuroimaging
  • High-resolution vessel wall imaging
  • Cerebral ischemia
  • Cerebral artery
03

In context

Intracranial Thrombosis

26 studies on the registry are indexed under Intracranial Thrombosis; 9 are open to participants now.

This study's planned enrollment of 100 is below the median of 256 across 14 observational studies indexed under Intracranial Thrombosis.

Browse Intracranial Thrombosis studies →

Lead sponsor

Chinese PLA General Hospital is the lead sponsor of 558 studies on the registry; 202 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Participants who are confirmed to have extracranial and/or intracranial artery occlusion

Inclusion criteria

  • Age ≥ 18 years
  • Extracranial and/or intracranial artery occlusion confirmed by angiography
  • Available for magnetic resonance high-resolution vessel wall imaging
  • Written informed consent obtained

Exclusion criteria

Exclusion Criteria:

  • Extracranial and/or intracranial artery mild to moderate stenosis
  • Pregnant women
  • Restenosis or occlusion after artery stenting placement
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Interventions

  • Diagnostic testthrombus imaging appearance

    Imaging appearance of intracranial and/or extracranial arterial thrombus

06

What researchers measure

Primary outcomes

  1. Rate of Successful Recanalization

    Antegrade blood flow through the recanalized portion was assessed by thrombolysis in myocardial infarction (TIMI) score or thrombolysis in cerebral infarction (TICI) score. TIMI≥2 or TICI≥2b was defined as successful recanalization.

    Time frame: 1-3 Years

  2. Ischemic Stroke Occurrence

    Ischemic stroke occurrence during follow-up period which was confirmed by neuroimaging

    Time frame: 1-3 Years

Secondary outcomes

  1. Number of Participants with Adverse Events

    hemorrhagic or ischemic stroke after recanalization treatment

    Time frame: 1-3 Years

07

Study locations

1 of 1 sites recruiting
  • Chinese PLA General Hospital
    Beijing, Beijing 100853, China
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05663281
Lead sponsor
Chinese PLA General Hospital
Responsible party
Jinhao Lyu (Attending physician, Chinese PLA General Hospital) — Principal investigator
First posted
Dec 23, 2022
Start date
Dec 15, 2022
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jul 3, 2024

Study contacts

Jinhao Lyu, M.D.
Contact
330322990@qq.com
+8615903562929

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion